Alto Neuroscience Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
ANRO$27.80+10.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash & cash equivalents | $82,548 | $48,344 |
| Other receivables | 8 | 333 |
| Prepaid expenses and other current assets | 2,835 | 543 |
| Total current assets | 85,391 | 49,220 |
| Property and equipment, net | 1,106 | 1,173 |
| Other assets | 131 | 461 |
| Total assets | $86,628 | $50,854 |
| Liabilities, convertible preferred stock and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,074 | $1,606 |
| Accrued expenses and other current liabilities | 4,536 | 3,954 |
| Total current liabilities | 5,610 | 5,560 |
| Term loan, non-current | 9,861 | 9,465 |
| Preferred stock warrant liability | 1,352 | 1,877 |
| Other long-term liabilities | — | 123 |
| Total liabilities | 16,823 | 17,025 |
| Commitments and contingencies (Note 14) | ||
| Convertible preferred stock: | ||
| Series Seed preferred stock (par value $0.0001), 3,708,682 shares authorized, issued and outstanding as of December 31, 2023 and 2022 | 7,674 | 7,674 |
| Series A preferred stock (par value $0.0001),7,250,992 and 7,337,133 shares authorized; 6,785,075 shares issued and outstanding as of December 31, 2023 and 2022 | 30,489 | 30,489 |
| Series B preferred stock (par value $0.0001), 9,876,955 and 10,651,260 shares authorized; 9,876,955 and 5,710,288 shares issued and outstanding as of December 31, 2023 and 2022 | 58,918 | 34,072 |
| Series C preferred stock (par value $0.0001), 10,674,967 and 0 shares authorized; 9,547,802 and 0 shares issued and outstanding as of December 31, 2023 and 2022 | 44,396 | — |
| Stockholders’ deficit: | ||
| Common stock (par value $0.0001), 52,000,000 and 36,200,000 shares authorized; 3,832,134 and 3,763,644 shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Additional paid-in capital | 5,372 | 2,300 |
| Accumulated deficit | (76,965) | (40,660) |
| Accumulated other comprehensive loss | (79) | (46) |
| Total stockholders’ deficit | (71,672) | (38,406) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $86,628 | $50,854 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.